Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 31-40 results of 79
Lung Cancer

CTSU S1827

Official Title: Testing Whether the Of Brain Scans Alone Instead Of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Study Purpose: To see if the use of brain scans alone instead of brain scans plus preventive brain radiation affect the lifespan of patients with small cell lung cancer.
Status: Recruiting
Gastrointestinal Cancer

EA2192

Official Title: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Study Purpose: To see if treating with olaparib compared to the usual approach which is observation,  is more successful in preventing pancreatic cancer from coming back 
Status: Recruiting
Gastrointestinal Cancer

ECOG-ACRIN EA2182

Official Title: Study Lower-Dose Chemoradiation for Early-Stage Anal Cancer
Study Purpose: To compare lower-dose chemoradiation therapy to standard-dose chemoradiation therapy and to find out if this approach is better or worse than the usual approach for anal cancer.
Status: Recruiting
Head and Neck Cancer

ECOG-ACRIN EA3132

Official Title: Testing The Addition Of Chemotherapy Drug, Cisplatin, To Usual Radiation Therapy For Patients With Head And Neck Cancer
Study Purpose: To compare two treatment approaches currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone.  A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.
Status: Recruiting
Head and Neck Cancer

ECOG-ACRIN EA3191

Official Title: Testing What Happens When An Immunotherapy Drug (Pembrolizumab) Is Added To Radiation Or Given By Itself Compared To The Usual Treatment Of Chemotherapy With Radiation After You Have Had Surgery For Your Recurrent Squamous Cell Carcinoma Of The Head And Neck
Study Purpose: To compare usual approach (chemotherapy plus radiation) to pembrolizumab alone and pembrolizumab in combination with radiation after having head and neck cancer surgically removed.
Status: Recruiting
Lung Cancer

ECOG-ACRIN EA5162

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions.
Status: Recruiting
Skin Cancer

ECOG-ACRIN EA6141

Official Title: Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma
Study Purpose: To compare any good and bad effects of giving three drugs- ipilimumab, nivolumab, and sargramostim at the same time compared to just ipilimumab and nivolumab together.
Status: Recruiting
Skin Cancer

ECOG-ACRIN EA6174

Official Title: Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery
Study Purpose: To see if the chance of cancer growing back can be lowered by adding the study drug, pembrolizumab, after surgery.
Status: Suspended
Lung Cancer

Genentech BO45217

Official Title: Phase III Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib versus Sotorasib or Divarasib in patients with previously treated KRAS G12C-positive Advanced or Metastatic NSCLC
Study Purpose: To evaluate the effectiveness of divarasib compared to currently approved Sotorasib or Adagrasib
Status: Pending
Gynecologic Cancer

GOG-3078/IMGN853-0421 GLORIOSA

Official Title: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Study Purpose: To compare progression-free survival after platinum-based chemotherapy (doublet) plus bevacizumab and randomized to maintenance mirvetuxemab sorvtansine (MIRV) plus bevacizumab (Arm 1) versus bevacizumab alone (Arm 2)
Status: Recruiting